Check out your Company Bowl for anonymous work chats.
A unique feature of Verily Site CTMS, our clinical trial management system, is protocol digitization. That means taking a study protocol in PDF format and creating a structured, digital version. The use of AI can further expedite the digitization process, with the goal of enabling site research operations teams to increase the productivity and revenue of their research programs. In this study, Verily researchers demonstrated that a fine-tuned LLM (PaLM-2) model can achieve near optimal performance without requiring manual labeling, a process that is both expensive and time-consuming. Our results show that using high confidence labels generated by LLM models such as Gemini-pro can be an efficient strategy for improving LLM performance on specialized tasks such as protocol digitization. Next week at the Machine Learning for Healthcare 2024 Conference we will present this work in the research track.
A clinical trial management system (CTMS) connects, organizes and simplifies the many aspects of research site operations, freeing clinical study sites to work on other tasks. The best CTMS systems can seamlessly work together to connect data from other software and tools, such as EHRs, regulatory eBinders and patient payment systems. Learn about our solution, Viewpoint Site CTMS, designed by researchers for researchers.
Despite innovations in clinical trial design, the ways to access, acquire and use data in trials has evolved very little over time. It remains expensive, labor-intensive and limits the amount of evidence that can be collected to inform whether and how care solutions work for different patient populations. In a new paper published in JAMA, experts in clinical trials, including from Verily, explore how to overcome these limitations and propose a modern data infrastructure for clinical research. The vision addresses two critical opportunities where an updated data infrastructure is essential: 1️⃣ Bringing together data sources that are not traditionally used for clinical research, to produce better and more generalizable insights into health. 2️⃣ Maximizing the research value of data by enabling the reuse of data for multiple purposes when necessary permissions are in place. The paper describes how a modernized data infrastructure can build on existing work in this area and also emphasizes important ethical considerations.
We are proud to announce that Verily Retinal Camera (Investigational Retinal Camera) has been selected to be used in retinal image data collection for the National Eye Institute (NEI)’s eyeGENE® registry due to its image quality, ease-of-use and portability. The core mission of eyeGENE® is to facilitate research into the causes and mechanisms of rare inherited eye diseases and accelerate pathways to potential treatments. With the addition of retinal images from the Verily Retinal Camera, we hope to provide the vision research community with another tool to advance ophthalmic research. The first study to use Verily Retinal Camera will research patients with albinism and hypopigmentation, with images collected at the NOAHCon 2024 National Conference. CAUTION - Investigational device. Limited by United States law to investigational use.
Our new cardiometabolic care solution, Verily Lightpath, will help members meet and maintain cardiometabolic health goals through access to an AI helper, designed to inform personal pathways, monitor behavior, and support engagement.* *To be available for open enrollment in early 2026
The most potential for AI in healthcare is in improving, not replacing, what physicians can do for a patient, says Andrew Trister, MD PhD, our Chief Medical and Scientific Officer. By taking longitudinal data that is incorporated from a patient’s health record and sources like wearable devices, AI can be applied to gain insight for faster treatment. Dr. Trister will be speaking in depth about AI’s potential to inform the learning health system at American Society of Clinical Oncology (ASCO) Breakthrough on August 8. Get a preview of his keynote.
Happy National Intern Day to our interns! They join us from University of Waterloo, University of Windsor, University of California, Berkeley, University of Illinois Urbana-Champaign and Harvard Business School to learn and contribute to Verily’s purpose of bringing precision health to everyone, every day. We are thrilled to have these future leaders be a part of hashtag#LifeAtVerily this summer ☀️
Today, Verily is changing our corporate headquarters from South San Francisco, CA to Dallas, Texas. Since opening our Dallas office three years ago, Verily has become an active leader in the growing DFW healthcare and tech ecosystem. The area offers a growing talent pool in health and technology and provides a central US office location for Verily to bridge our east and west coast locations – where we continue to invest and grow our presence in the SF Bay Area, Boston, Greater Toronto and Raleigh. As the industry and regional population grow in Dallas, we look forward to our continued contributions as an economic player and community leader in the years ahead. We’re hiring! Check out our openings.
Verily Lightpath Metabolic programs* for health plans will be a smart, dynamic and personalized approach to help manage diabetes, obesity, hypertension and more. Explore the AI-powered metabolic care offerings, backed by deep clinical expertise. *To be available for open enrollment in early 2026
The Verily team recently attended AHIP 2024, the leading industry conference for health insurance plans. Verily leaders weighed in on the challenges health plans face and the tech solutions designed to drive more personalized care. Here are the top 3 highlights from the show floor: 1️⃣ Dr. Vindell Washington on health equity: “One of the guiding product inclusion principles is that health equity doesn’t sit to the side of the solution.” 2️⃣ Yes, AI-powered care can be effective, but it relies on high-quality data and regulatory safety measures. 3️⃣ GLP-1s and virtual programs must combine to create real value. Verily also announced its launch of Verily Lightpath Metabolic, an AI-powered precision virtual care solution to be available for open enrollment beginning in January 2026.
